Literature DB >> 30882858

Immune Profiling of Thyroid Carcinomas Suggests the Existence of Two Major Phenotypes: An ATC-Like and a PDTC-Like.

Riccardo Giannini1, Sonia Moretti2, Clara Ugolini1, Elisabetta Macerola1, Elisa Menicali2, Nicole Nucci2, Silvia Morelli2, Renato Colella3, Martina Mandarano3, Angelo Sidoni3, Matteo Panfili4, Fulvio Basolo1, Efisio Puxeddu2.   

Abstract

OBJECTIVES: The understanding of the mechanisms underlying thyroid cancer immune escape can lead to the identification of new molecular targets and/or efficacy biomarkers. For this purpose, we performed immune expression profiling in thyroid cancers to obtain a comprehensive view on immune mechanisms activated during cancer progression.
METHODS: The study was conducted retrospectively in 25 papillary thyroid carcinomas (PTCs), 14 poorly differentiated thyroid carcinomas (PDTC), 13 anaplastic thyroid carcinomas (ATCs), and 7 normal thyroid (NT) tissue samples. Gene expression profiling was obtained on RNA samples using the Nanostring platform and its nCounter PanCancer Immune Profiling Panel.
RESULTS: Gene expression comparison of ATC, PTC, and PDTC vs NT showed high number of regulated genes in cancer samples. In detail, immune-related gene sets were significantly upregulated (ATC > PTC > > PDTC). Most ATC and approximately half of PTC showed a microenvironment infiltrated by macrophages and T-cells with CD8+ effector phenotype, part of which appeared to be functionally exhausted. Conversely, most PDTC, as NT samples, as the remaining part of PTC, displayed a poor or absent infiltration by immune cells. Interestingly, an upregulation of inhibitory immune checkpoint mediators, including PDL1, PDL2, PD1, LAG-3, TIM-3, PVR, and TIGIT, could be detected in ATC and PTC.
CONCLUSIONS: These data indicated the existence of two major immune phenotypes in thyroid carcinoma: an ATC-like one, including hot and altered-immunosuppressed tumors and a PDTC-like one, including altered-excluded and cold tumors. Confirmation of the findings in locally advanced or metastatic cancer tissues is expected to have important immunotherapeutic implications.
Copyright © 2019 Endocrine Society.

Entities:  

Mesh:

Year:  2019        PMID: 30882858     DOI: 10.1210/jc.2018-01167

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  23 in total

1.  Metastatic Anaplastic Thyroid Carcinoma in Complete Remission: Morphological, Molecular, and Clinical Work-Up of a Rare Case.

Authors:  Adam Stenman; L Samuel Hellgren; Kenbugul Jatta; Martin Hysek; Maja Zemmler; Renske Altena; Inga-Lena Nilsson; Robert Bränström; Jan Zedenius; C Christofer Juhlin
Journal:  Endocr Pathol       Date:  2020-03       Impact factor: 3.943

2.  PD1 Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer.

Authors:  Katherine D Gray; Jaclyn E McCloskey; Yogindra Vedvyas; Olivia R Kalloo; Steve El Eshaky; Yanping Yang; Enda Shevlin; Marjan Zaman; Timothy M Ullmann; Heng Liang; Dessislava Stefanova; Paul J Christos; Theresa Scognamiglio; Andrew B Tassler; Rasa Zarnegar; Thomas J Fahey; Moonsoo M Jin; Irene M Min
Journal:  Clin Cancer Res       Date:  2020-09-04       Impact factor: 12.531

3.  Disruption of Cell-Cell Communication in Anaplastic Thyroid Cancer as an Immunotherapeutic Opportunity.

Authors:  Sanjukta Chakraborty; Michelle Carnazza; Tara Jarboe; Nicole DeSouza; Xiu-Min Li; Augustine Moscatello; Jan Geliebter; Raj K Tiwari
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4. 

Authors:  茜璇 卢; 黎莎 包; 宗富 潘; 明华 葛
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2021-12-25

Review 5.  Immunotherapy for anaplastic thyroid carcinoma: the present and future.

Authors:  Xixuan Lu; Lisha Bao; Zongfu Pan; Minghua Ge
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2021-12-25

6.  Integrated analysis of novel macrophage related signature in anaplastic thyroid cancer.

Authors:  Yi Luo; Yi-Chen Yang; Ben Ma; Wei-Bo Xu; Tian Liao; Yu Wang
Journal:  Endocrine       Date:  2022-09-07       Impact factor: 3.925

7.  The miR-199a-5p/PD-L1 axis regulates cell proliferation, migration and invasion in follicular thyroid carcinoma.

Authors:  Jianguang Lin; Yanru Qiu; Xueqin Zheng; Yijun Dai; Tianwen Xu
Journal:  BMC Cancer       Date:  2022-07-11       Impact factor: 4.638

Review 8.  Immunotherapy for advanced thyroid cancers - rationale, current advances and future strategies.

Authors:  Jena D French
Journal:  Nat Rev Endocrinol       Date:  2020-08-24       Impact factor: 43.330

Review 9.  Immune Landscape of Thyroid Cancers: New Insights.

Authors:  Elisa Menicali; Martina Guzzetti; Silvia Morelli; Sonia Moretti; Efisio Puxeddu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-27       Impact factor: 5.555

Review 10.  The Genomic Landscape of Thyroid Cancer Tumourigenesis and Implications for Immunotherapy.

Authors:  Amandeep Singh; Jeehoon Ham; Joseph William Po; Navin Niles; Tara Roberts; Cheok Soon Lee
Journal:  Cells       Date:  2021-05-01       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.